post roughli in-lin hand challeng drove soft top
line modest trim guidanc headwind bear
watch think core lab driver remain firmli intact expect bolster
volum pama acceler share gain view well posit
low cost/high qualiti provid market move toward valu
remain strong patient satisfaction/digit effort promis retail touch
point expand maintain hold trim pt
ep vs reflect modestli lower growth expect
roughli in-lin result soft top line revenu
came shi consensu quarter saw slightli
lower volum bp organ bp declin revenue/
requisit vs volum weak tie tepid growth
hep drug monitor vitamin test bp aggreg well
increas rate denial patient pay make larger portion overal
revenu continu progress cost savings/oper effici provid
off-set produc adjust ebit margin bp ahead
think drive adjust ebit roughli in-lin
pama impact bp in-lin expect adjust
ep three cent ahead estim lower tax rate
compani make headway headwind vitamin drug
monitor patient concess would expect portion impact
persist
retail strategi patient access initi focu improv
patient access/experi remain acut compani seen earli
progress sever initi initi result
nr partnership encourag increas volum locat
open month vs psc replac current
locat insid store tx fl il combin
safeway privat expect hit retail locat year end
addit digit invest gain traction user
myquest app user view test result schedul appoint pay
bill see psc wait time new schedul system better optim patient
conveni increas adopt on-line specimen pickup
sequenti lastli compani launch quest clinic trial connect
june new patient recruit servic help pharma locat
interest patient fit trial need
tr target
adjust non-control interest equiti
earn jv
guidanc trim put take conjunct earn manag lower
full year guidanc revenu adjust ep
 reflect headwind experienc ytd addit initi expect
headwind tailwind provid includ increment volum
contract buy revenu growth alreadi achiev recent announc
acquisit challeng uptick pama impact bp
bp reimburs pressur beyond pama third parti payor vs normal
move network continu expect mix off-set sizabl chunk headwind
manag expect grow revenu earn stand compound-annual-growth-rate
pama updat opportun quest expect impact pama
wane hope around pama fix expect see acceler a/
partnership opportun think compani could see attract multipl time
continu view well posit weather pama given size sophist rel
low exposur medicar strong gener clean balanc sheet compani
plenti dri powder capit strateg opportun
remain solid adjust estim flow trend remain solid cffo
respect vs strhe addit compani
announc three acquisit phenopath oxford immunotec reprosourc
expand quest capabl across number area includ molecular oncolog infecti
diseas diagnost reproduct diagnost addit repurchas share
 trim estim adj ep
reflect modestli conserv top-lin margin assumpt
page
servic
revenu
revenu
amort intang
equiti earn jv
revenu
equiti earn jv net tax
page
base teterboro nj lead provid diagnost test inform
relat servic compani offer patient physician access diagnost laboratori
servic nation network region laboratori patient servic center
addit rapid respons laboratori compani also offer esoter test includ gene-
base test substanc abus test anatom patholog servic test clinic trial
clinic lab remain integr part healthcar deliveri model diagnost test
critic compon treatment decis process uncertainti around reimburs increas
applaud recent step manag drive sharehold valu reimburs bear
watch volum growth remain key
valuat risk
price target base trade cash ep slight premium
current multipl view appropri given solid underli trend strong free cash flow
gener ramp contribut profession lab servic risk rate price target
upsid includ acceler volum growth improv price potenti accret
downsid risk includ deceler volum stronger anticip reimburs headwind
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
